GUILFORD, Conn. USA, and TOKYO, Japan, December 16, 2021 — InveniAI® LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and development, and Kyowa Kirin Co., Ltd. (Kyowa Kirin), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, expanded their longstanding relationship with a new, multiple drug discovery agreement.
The collaboration will provide Kyowa Kirin with access to InveniAI's AI Innovation Lab and AI Technology Platform, AlphaMeld®, to expand the scope of Kyowa Kirin's drug discovery programs. InveniAI will receive a committed annual research funding fee for the duration of the collaboration term and obtain rights to receive milestone payments and royalties on sales from Kyowa Kirin.
The agreement builds on an ongoing partnership between InveniAI and Kyowa Kirin that began in 2018. The collaboration enables Kyowa Kirin to access InveniAI's AI technology platform, AlphaMeld®, its AI Innovation Lab, and a dedicated team of experts to drive drug discovery efforts across Kyowa Kirin's therapeutic areas, platforms, and modalities.
Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin, said, "We are excited about the strategic expansion of our partnership, as it is designed to seamlessly integrate InveniAI's AI capabilities with our therapeutic platforms to facilitate the discovery of valuable new therapies for patients. Our collaboration, to date, is a testament to the importance of a data-driven approach."
"We are pleased to expand our collaboration with Kyowa Kirin, with whom we share a common philosophy of leveraging data and technology to de-risk drug development and deliver better therapies to patients more efficiently," said Krishnan Nandabalan, Ph.D., President and CEO, InveniAI LLC. "InveniAI is the only AI company with a track record that includes an AI-identified candidate that has undergone successful Phase 3 trials and an NDA submission, in addition to ten other programs at various stages of development."